Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Inhibikase Therapeutics, Inc. | Director | Common Stock | 145K | $199K | $1.37 | Oct 21, 2024 | Direct |
RayzeBio, Inc. | CHIEF FINANCIAL OFFICER | Common Stock | 0 | $0 | $62.50 | Feb 26, 2024 | Direct |
Inhibikase Therapeutics, Inc. | Director | Stock Option (right to buy) | 60K | Oct 21, 2024 | Direct | ||
RayzeBio, Inc. | CHIEF FINANCIAL OFFICER | Employee Stock Option (right to buy) | 0 | Feb 26, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
IKT | Inhibikase Therapeutics, Inc. | Oct 21, 2024 | 2 | $199K | 4 | Oct 23, 2024 | Director |
IKT | Inhibikase Therapeutics, Inc. | Oct 21, 2024 | 0 | $0 | 3 | Oct 23, 2024 | Director |
RYZB | RayzeBio, Inc. | Feb 26, 2024 | 4 | -$4.9M | 4 | Feb 27, 2024 | CHIEF FINANCIAL OFFICER |
RYZB | RayzeBio, Inc. | Nov 17, 2023 | 1 | $0 | 4 | Nov 17, 2023 | Chief Financial Officer |
RYZB | RayzeBio, Inc. | Sep 14, 2023 | 0 | $0 | 3 | Sep 14, 2023 | Chief Financial Officer |